Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ®, today announced that an abstract entitled “Combined Safety and ...
IDE supplement expands trial to the other primary standard-of-care chemotherapy for pancreatic cancer patients, alongside mFOLFIRINOX -- IDE ...
JERUSALEM, April 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (DRTS) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ®, announced today that the ...
HekaBio K.K., (Headquarters: Chuo-ku, Tokyo) announces that the innovative solid tumor treatment device 'Alpha DaRT (Diffusing Alpha Radiation Therapy),' developed by Alpha Tau Medical Ltd.
ACAPELLA is the European multicenter clinical trial evaluating Alpha DaRT alpha-emitter radiotherapeutics combined with capecitabine for ...
Alpha Tau Medical pioneers localized alpha particle radiation for solid tumors, with its Alpha DaRT technology showing broad applicability and strong early efficacy. 2026 is pivotal for DRTS, with ...
CLEVELAND, Ohio — The Ohio State University’s James Cancer Hospital has treated the world’s first brain cancer patient to receive a new radiation technology that attacks tumors from within, the ...
Mr. Levy will be available for 1x1 investor meetings. Please reach out to your Jefferies representative to schedule. About Alpha Tau Medical Ltd. Founded in 2016, Alpha Tau is an Israeli oncology ...
Alpha Tau Medical Ltd ( (DRTS)) has issued an announcement. On April 23, 2026, Alpha Tau Medical announced that it has successfully treated the first European pancreatic cancer patient with its Alpha ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results